RhettMeadSchiffmanMDMS MHSA

Ophthalmology • Irvine, CA

Physician

Join to view full profile

Dr. Schiffman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Schiffman's full profile

Already have an account?

Office
118 Med Surge # 1
Irvine, CA 92697
Phone+1 949-824-6211

Fax+1 949-824-4015

Education & Training

Henry Ford Health/Henry Ford HospitalResidency, Ophthalmology, 1993 - 1996
Henry Ford Health/Henry Ford HospitalResidency, Internal Medicine, 1983 - 1986
Universidad Autonoma de Ciudad JuarezClass of 1982

Certifications & Licensure

CA State Medical License 2002 - 2025
MI State Medical License 1984 - 2004
American Board of Internal Medicine Internal Medicine
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

Fellow (FAAO) American Academy of Ophthalmology

Clinical Trials

Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) Start of enrollment: 2014 Sep 01
Terminated
Phase 1, Phase 2

Publications & Presentations

PubMed

2049 citations
Reliability and validity of the Ocular Surface Disease Index.
Rhett M. Schiffman, Murray Dale Christianson, Gordon Jacobsen, Jan D. Hirsch, Brenda L. Reis
Archives of Ophthalmology. 2000-05-01
479 citations
Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis
Careen Y. Lowder, Rubens Belfort, Susan Lightman, C. Stephen Foster, Michael R. Robinson
Archives of Ophthalmology. 2011-05-09
247 citations
Utility assessment among patients with dry eye disease.
Rhett M. Schiffman, John G. Walt, Gordon Jacobsen, John Doyle, Gary Lebovics
Ophthalmology. 2003-07-01

Press Mentions

Phase 3 Presbyopia Drop Trial LaunchesApril 6th, 2022
Visus Therapeutics Appoints Industry Leaders Tracy Valorie and Dwight Moxie to Board of DirectorsAugust 25th, 2021
Visus Therapeutics Expands Ophthalmic Drug Portfolio with Investigational Therapies for Glaucoma and Age-Related Macular Degeneration; Secures Exclusive License for Novel Ophthalmic Drug Delivery TechnologyAugust 19th, 2021
Join now to see all

Professional Memberships

American Academy of Ophthalmology - AAO
Fellow